# Cochrane Systematic Reviews the best evidence

#### Professor Richard Hughes Cochrane NMD Group London rhughes11@btinternet.com



# Disclosures

- Consultancies
  - BMS, CSL Behring, Grifols, LFB, Merck, Novartis
- Co-ordinating editor
  - Cochrane Neuromuscular Disease Group
     1998 2008
- President
  - EFNS 2010 2014

# Learning objectives

To be able to explain

- Differences between systematic and nonsystematic reviews
- Risk of bias
- Forest plots
- Risk ratios, odds ratios, numbers needed to treat
- How to access the Cochrane library

# Hierarchy of evidence 1

Class I: Adequately powered randomized, controlled trial or systematic review with masked outcome assessment in representative population with

- a. randomization concealment
- b. primary outcome(s) clearly defined
- c. exclusion/inclusion criteria are clearly defined
- d. dropouts and crossovers accounted for and few
- e. baseline characteristics equivalent or appropriately adjusted

# Hierarchy of evidence 2

Class I: Adequately powered randomized, controlled trial or systematic review with masked outcome assessment in representative population fulfilling a-e

Class II: Prospective matched-group cohort study in representative population with masked outcome assessment meeting a-e or a randomized trial in a representative population lacking one of a-e

Class III: All other controlled trials where outcome assessment is independent of patient treatment

Class IV: Uncontrolled studies, case series, case reports, or expert opinion

A woman woke with a complete facial palsy, was given cortisone 100 mg four times daily, and recovered in 7 days.

It is indeed difficult, though tempting, to draw a conclusion from a single satisfactory case.

#### Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials Gordon C S Smith, Jill P Pell 2003 BMJ 327 1459-61

#### What this study adds

No randomised controlled trials of parachute use have been undertaken

The basis for parachute use is purely observational, and its apparent efficacy could potentially be explained by a "healthy cohort" effect

Individuals who insist that all interventions need to be validated by a randomised controlled trial need to come down to earth with a bump



See also Glasziou 2007 BMJ 334 349

### Scurvy: controlled trial Lind J 1753 A Treatise of the scurvy

- a quart of cider
- 75 drops of vitriol elixir
- 6 spoons of vinegar
- half a pint of seawater
- three nutmegs
- two oranges and a lemon



#### Bell's palsy steroids randomised controlled trial Taverner D 1954 Lancet 2 1052

26 patients with complete facial palsy randomised within 9 days after onset to cortisone starting dose 200 mg orally daily for 3 days, 100 mg daily for 4 days and 50 mg daily for 2 days or placebo

Randomised double blind Concealed allocation Balanced clinical features at baseline Complete follow-up Intention to treat analysis

Developed denervation Mean (range) days to recovery **Risk ratio 0.85 (0.21 – 3.38)** 

Steroid	Control
4/14	4/12
63 (27 – 105)	<b>69</b> (18-157)

# In 1972 one of the 'fathers' of Evidence-Based Medicine, Archie Cochrane, said

"It is surely a great criticism of our profession that we have not organised a critical summary, by speciality or sub-speciality, updated periodically, of all relevant randomised controlled trials."





# A history of the Cochrane Collaboration

- 1972 Publication of Archie Cochrane's '<u>Effectiveness and Efficiency: random</u> <u>reflections on health services</u>', which drew attention to our collective ignorance about the effects of health care
- 1985-90 International collaboration to prepare systematic reviews of controlled trials in pregnancy and childbirth
- 1992 'The Cochrane Centre' opens in Oxford, UK
- 1993 Formal launch of The Cochrane Collaboration at the 1st Cochrane Colloquium, in Oxford, UK
- 1998 Neuromuscular Diseases Group registered
- 2002 The Cochrane Library free at the point of use to anyone with Internet access in England and for developing countries


2012 - The number of Cochrane Reviews in the CDSR exceeds 5,000

## The Cochrane Collaboration


- International network of more than 28,000 people from over 100 countries.
- Over 5,000 Cochrane reviews so far, published online in the Cochrane Database of Systematic Reviews, part of *The Cochrane Library.*
- Each review takes hundreds of hours and a team of people to produce.
- Over 2,000 protocols for Cochrane Reviews available
- The latest estimate is that at least 10,000 Cochrane Reviews are needed to cover all healthcare interventions that have already been investigated in controlled trials
- These reviews will need to be updated at the rate of 5,000 per year.

[Source: http://www.cochrane.org (accessed 18 June 2013)]

# Cochrane reviews progress



# Preparing a Cochrane Review



# Differences between a non-systematic review, systematic review and Cochrane review

#### Non-systematic review


- Overview
- Search not defined
- Selection of studies not defined

- Personal bias of the authors
- Paper publication

#### Cochrane systematic review

- Defined research question
- Search strategy
- Studies defined
  - type of study
  - participants
  - methodological quality
- Peer review
- Electronic publication
- Electronic criticisms
- Electronic updating

#### Cumulative meta-analysis



/w.thecochranelibrary.com/view/0/index.l 🔎 👻 🖻 🛛 🎯 H	ome - The Cochrane Libr ×	
I 🗿 http 😢 BT Y 🌑 BBC 餐 Coch 👁 Inte 🛔	iGoo 🧃	
	IDDADY	
Independent high-quality evidence		from ]
SEARCH THE COCHRANE LIBRARY		
Title, Abstract, Keywords		r n
Bells palsy X GO	HOME 🏡 SIGN UP 🥜	LEARN 👘 ACCESS 🔓
or try an <u>Advanced Search</u>		
COCHRANE DATABASE OF SYSTEMATIC	SPECIAL COLLECTIONS	EDITORIALS
REVIEWS Issue 6 of 12, June 2013	World day for Safety and Health at Work 2013	Folic acid supplementation for rheumatoid arthritis patients on
(Updated Daily)  Contents		methotrexate: the good gets better
BROWSE BY TOPICS	Preventing falls and fall- related injuries in older	Jasvinder Singh
Note: numbers shown below are wrong and will be corrected soon.	people	Calling time on intravenous immunoglobulin for preterm
Anaesthesia & pain control (1051)	Tuberculosis	infants?
Blood disorders (678)		Roger Soll

All Resu	ılts (135)	Cochrane Database of Systematic Reviews : Issue 7 of 12, July 2013	
Coch	nrane Reviews (7)	Issue updated daily throughout month	
		There are 7 results from 8026 records for your search on 'Bells palsy in title abstract keywords in Coo	hrane Reviews'
_	otocol	Sort by	Relevance 🗸
100 million 192	r Reviews (18)	Select all Export all Export selected	
O Tech O Econ	nods Studies (1) nology Assessments (2) nomic Evaluations (1)	Hyperbaric oxygen therapy for Bell 's palsy N Julian Holland , Jonathan M Bernstein and John W Hamilton February 2012	Review
<ul> <li>All</li> <li>Curre</li> </ul>	nrane Groups (0) ent Issue	Acupuncture for Bell 's palsy Ning Chen , Muke Zhou , Li He , Dong Zhou and N Li August 2010	Ns Review
Dg Ov	Methodology Diagnostic Overview Conclusions changed	Surgical interventions for the early management of <b>Bell</b> 's <b>palsy</b> Kerrie McAllister , David Walker , Peter T Donnan and Iain Swan February 2011	Review
Мс	New search Major change Update	Antiviral treatment for <b>Bell</b> 's <b>palsy</b> (idiopathic facial paralysis) Pauline Lockhart , Fergus Daly , Marie Pitkethly , Natalia Comerford and Frank Sullivan June 2010	Review
_	Withdrawn Comment	Corticosteroids for <b>Bell</b> 's <b>palsy</b> (idiopathic facial paralysis) Rodrido A Salinas . Gonzalo Alvarez . Ferdus Dalv and Joaquim Ferreira	


#### Bell's palsy steroids Cochrane review

Salinas et al 2010 Cochrane Database of Systematic Reviews Issue 2

#### Incomplete recovery after 6 months or more

Corticosteroids		Contr	ol	Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Engström 2008a	63	213	82	209	33.6%	0.75 [0.58, 0.98]	-
Engström 2008b	86	210	103	207	42.1%	0.82 [0.67, 1.02]	
May 1976	10	25	9	26	3.6%	1.16 [0.57, 2.36]	
Sullivan 2007a	5	138	18	141	7.2%	0.28 [0.11, 0.74]	
Sullivan 2007b	8	134	27	138	10.8%	0.31 [0.14, 0.65]	
Taverner 1954	3	13	3	11	1.3%	0.85 [0.21, 3.38]	
Unuvar 1999	0	21	3	21	1.4%	0.14 [0.01, 2.61]	
Total (95% CI)		754		753	100.0%	0.71 [0.61, 0.83]	•
Total events	175		245				
Heterogeneity: Chi <sup>2</sup> =	: 13.47, df = 6	6 (P = 0.0	04); I <sup>2</sup> = 5	5%			
Test for overall effect	여름 하지 않는 것을 많이 없는 것이 없다.	199 <b>0</b> - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999					0.002 0.1 1 10 500 Favours treatment Favours control

# **Risk of bias**



## odds versus risk ratios

	+	-	Total
Placebo	а	b	a + b
Treatment	С	d	c + d

Odds ratio (OR) = (a/b)/(c/d)Risk ratio (RR) = [a/(a+b)]/[c/(c+d)]

Relative risk reduction = 1 - RR

Absolute risk reduction (ARR) = a/(a+b) - c/(c+d)

Number needed to treat = 1/ARR

#### Bell's palsy steroids Cochrane review

Salinas et al 2010 Cochrane Database of Systematic Reviews Issue 2

#### Incomplete recovery after 6 months or more

	Corticoste	roids	Contr	ol		<b>Risk Ratio</b>	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	
Engström 2008a	63	213	82	209	33.6%	0.75 [0.58, 0.98]		
Engström 2008b	86	210	103	207	42.1%	0.82 [0.67, 1.02]		
May 1976	10	25	9	26	3.6%	1.16 [0.57, 2.36]		
Sullivan 2007a	5	138	18	141	7.2%	0.28 [0.11, 0.74]		
Sullivan 2007b	8	134	27	138	10.8%	0.31 [0.14, 0.65]		
Taverner 1954	8 3	13	3	11	1.3%	0.85 [0.21, 3.38]		
Unuvar 1999	0	21	3	21	1.4%	0.14 [0.01, 2.61]		
Total (95% CI)		754		753	100.0%	0.71 [0.61, 0.83]	•	
Total events	175		245					
Heterogeneity: Chi <sup>2</sup> =	13.47, df = 6	(P = 0.0	04); l <sup>2</sup> = 5	5%				-
Test for overall effect:	Z = 4.34 (P <	0.0001	)				Favours treatment Favours control	1
							1 avours treatment 1 avours control	
	ster	oid	contro					
Risk	23%		33%					
-		-						
Absolute risk		-	10%					
Number need	led to tre	at	10					

### IVIg for CIDP



# Risk ratio of improvement in disability with IVIg for CIDP

Study or subgroup	IVIg n/N	Placebo n/N	Risk Ratio M - H, Fixed, 95% Cl	Weight	Risk Ratio M-H,Fixed,95% Cl
1 Parallel design Mendell 2001	11/30	2/23		7.2 %	4.22 [1.03, 17.19]
Vermeulen 1993	4/15	3/13		10.2 %	1.16 [ 0.32, 4.24 ]
Hughes 2008	42/59	20/58		64.2 %	2.06 [1.40, 3.05]
<b>Subtotal (95% Cl)</b> Total events: 57 (IVIg), 25 (Pla Heterogeneity: Chi <sup>2</sup> = 1.79, df Test for overall effect: Z = 4.0	$f = 2 (P = 0.41); I^2$	<b>94</b> =0.0%	•	81.7 %	2.14 [ 1.48, 3.09 ]
2 Cross- over design Thompson 1996	2/7	0/7		1.6 %	5.00 [ 0.28, 88.53 ]
Hahn 1996	19/30	5/27		16.8%	3.42 [1.48, 7.90
<b>Subtotal (95% Cl)</b> Total events: 21 (IVIg), 5 (Plac Heterogeneity: Chi <sup>2</sup> = 0.06, df Test for overall effect: Z = 3.0	$f = 1 (P = 0.80); I^2$	<b>34</b> =0.0%	*	18.3 %	3.56 [ 1.59, 7.96
<b>Total (95% Cl)</b> Total events: 78 (IVIg), 30 (Pla Heterogeneity: Chi <sup>2</sup> = 3.34, df	<b>141</b> acebo) f = 4 (P = 0.50);   <sup>2</sup> 1 (P < 0.00001)	<b>128</b> =0.0%	٠	100.0 %	2.40 [ 1.72, 3.36 ]

# Summary of findings

Outcomes         Illustrative comparative risks* (95% CI)           Assumed risk         Corresponding risk           Placebo         IVIg	Illustrative compara	ntive risks* (95% CI)	Relative effect (95% Cl)	No of Participants (studies)	Quality of the evidence (GRADE)
	IVIg				
Significant improvement in disability scale used in original study Follow-up: 2 to 6 weeks		44 per 100 (32 to 62)	RR 2.4 (1.72 to 3.36)	269 <sup>1</sup> (5 studies)	⊕⊕⊕⊕ high

#### **CIDP** Treatment Overall 70% patients respond to Rx in short term

Corticosteroids for chronic inflammatory demyelinating Polyradiculoneuropathy 2002 Updated 2007 and 2012 Man Mohan Mehndiratta<sup>1</sup>, Richard AC Hughes<sup>2</sup> Authors' conclusions

A single randomised controlled trial with 35 participants provided weak evidence to support the conclusion from non-randomised studies that oral corticosteroids reduce impairment in CIDP. Corticosteroids are known to have serious long-term side effects. The long-term risk and benefits have not been adequately studied. [NB worsening may occur in motor CIDP]

Plasma exchange for chronic inflammatory demyelinating Polyradiculoneuropathy 2004 updated 2010 Man Mohan Mehndiratta<sup>1</sup>, Richard AC Hughes<sup>2</sup>, Puneet Agarwal<sup>3</sup>

Authors' conclusions Moderate to high guality evidence from two small trials [47 patients] showed that PEx provides significant short-

term improvement in disability, clinical impairment and motor nerve conduction velocity in CIDP but rapid deterioration may occur afterwards. Adverse events ..... are not uncommon.

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2004 Updated 2010 F Eftimov<sup>1</sup>, JB Winer<sup>2</sup>, M Vermeulen<sup>3</sup>, R de Haan<sup>4</sup>, I vanSchaik<sup>1</sup> Authors' conclusions

The evidence ..... shows that IVIG improves disability for at least two to six weeks compared with placebo, with a number needed to treat of 3.00..... it has similar efficacy to plasma exchange and oral prednisolone. In one large trial, benefit of IVIg persisted for 24 and possibly 48 weeks.





HE COCHRAN COLLABORATION





# Access to the Cochrane library





# Strengthening research and knowledge systems

INASP is an international development charity working with a global network of partners to improve access, production and use of research information and knowledge, so that countries are equipped to solve their development challenges.

#### Where we work

We work with over 22 partner countries and over 80 network countries around the world — find out what is happening in yours!



## Investigating capacity to use evidence

Time for a more objective approach? This reflective paper discusses why so many capacity building programmes fail to thoroughly assess skills gaps and determine what capacity is required before starting their activities.





~